News & Updates
Filter by Specialty:
Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
31 Jul 2023
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
Surveillance of favourable-risk patients with metastatic renal cell carcinoma (mRCC) using risk stratification based on the International mRCC Database Consortium (IMDC) and number of metastatic sites may be done following cytoreductive nephrectomy without initiating systemic therapy, suggests a recent study.
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
30 Jul 2023
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
Maintenance therapy with niraparib appears to increase progression-free survival (PFS) in patients with advanced ovarian cancer, irrespective of postoperative residual disease or biomarker status, according to data from the phase III PRIME study.
